Aarti Industries

The project has moved beyond technology finalization into the equipment delivery and environmental clearance stage. (1 met across 1 tracked commitment)

Management confirmed that the calcium chloride plant is expected to be commissioned within the current quarter (Q3 FY26) as previously guided. (1 met, 1 revised, 1 exceeded across 3 tracked commitments)

Domestic revenue share expanded significantly from 35% to 46%, indicating a stronger reliance on the home market and successful import substitution strategies. (1 expanding)

The company is aggressively expanding its cost moat through a dedicated 'Cost Optimisation' program targeting Rs 150-200 Cr in EBITDA impact. (5 expanding)

The MMA capacity expansion is progressing from a base of 23.1 KT in FY22 to 123 KT in FY25, with a massive jump to 260 KTPA scheduled for Q1 FY26. This represents a significant step-function growth in production capability. (5 accelerating across 5 signals, 3 leading indicators)

Aarti is investing in a new downstream project (PEDA) to integrate its ethylation products, which is expected to improve profit margins and capacity use.

The risk remains intensifying in terms of pricing. While volumes are recovering, overcapacity in China leads to 'marginal pricing' (selling at very low prices to cover basic costs), preventing an uptick in margins despite the end of destocking. (1 intensifying, 2 stable, 1 easing, 1 high-severity)

The risk is intensifying in terms of margin pressure. While volumes are growing, management notes that MMA margins are being compressed due to weak Gasoline-Naphtha cracks compared to FY24. (1 intensifying, 3 high-severity)